The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge

Janine L. Ferrant, Christopher D. Benjamin, Anne H. Cutler, Susan L. Kalled, Yen Ming Hsu, Ellen A. Garber, Donna M. Hess, Renee I. Shapiro, Norma S Kenyon, David M. Harlan, Allan D. Kirk, Linda C. Burkly, Frederick R. Taylor

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Blockade of the CD154-CD40 co-stimulatory pathway with anti-CD154 mAbs has shown impressive efficacy in models of autoimmunity and allotransplantation. Clinical benefit was also demonstrated in systemic lupus erythematosus (SLE) and idiopathic thrombocytopenia patients with the humanized anti-CD154 mAb, 5C8 (hu5C8). However, thromboembolic complications that occurred during the course of the hu5C8 clinical trials have proven to be a major setback to the field and safe alternative therapeutics targeting the CD154-CD40 pathway are of great interest. Recently, effector mechanisms have been shown to play a part in anti-CD154 mAb-induced transplant acceptance in murine models, while this issue remains unresolved for humoral-mediated models. Herein, aglycosyl anti-CD154 mAbs with reduced binding to FcγR and complement were used as a novel means to test the role of effector mechanisms in non-human primate and murine models not amenable to gene knockout technology. While aglycosyl hu5C8 mAb was relatively ineffective in rhesus renal and islet allotransplantation, it inhibited primary and secondary humoral responses to a protein immunogen in cynomolgus monkeys. Moreover, an aglycosyl, chimeric MR1 mAb (muMR1) prolonged survival and inhibited pathogenic auto-antibody production in a murine model of SLE. Thus, the mechanisms required for efficacy of anti-CD154 mAbs depend on the nature of the immune challenge.

Original languageEnglish
Pages (from-to)1583-1594
Number of pages12
JournalInternational Immunology
Volume16
Issue number11
DOIs
StatePublished - Nov 1 2004

Fingerprint

Systemic Lupus Erythematosus
Immunotherapy
Gene Knockout Techniques
Macaca fascicularis
Autoimmunity
Thrombocytopenia
Primates
Antibody Formation
Clinical Trials
Technology
Transplants
Kidney
Survival
Proteins
Therapeutics

Keywords

  • Antibody
  • Co-stimulation
  • FcR
  • Lupus
  • Transplantation

ASJC Scopus subject areas

  • Immunology

Cite this

Ferrant, J. L., Benjamin, C. D., Cutler, A. H., Kalled, S. L., Hsu, Y. M., Garber, E. A., ... Taylor, F. R. (2004). The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. International Immunology, 16(11), 1583-1594. https://doi.org/10.1093/intimm/dxh162

The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. / Ferrant, Janine L.; Benjamin, Christopher D.; Cutler, Anne H.; Kalled, Susan L.; Hsu, Yen Ming; Garber, Ellen A.; Hess, Donna M.; Shapiro, Renee I.; Kenyon, Norma S; Harlan, David M.; Kirk, Allan D.; Burkly, Linda C.; Taylor, Frederick R.

In: International Immunology, Vol. 16, No. 11, 01.11.2004, p. 1583-1594.

Research output: Contribution to journalArticle

Ferrant, JL, Benjamin, CD, Cutler, AH, Kalled, SL, Hsu, YM, Garber, EA, Hess, DM, Shapiro, RI, Kenyon, NS, Harlan, DM, Kirk, AD, Burkly, LC & Taylor, FR 2004, 'The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge', International Immunology, vol. 16, no. 11, pp. 1583-1594. https://doi.org/10.1093/intimm/dxh162
Ferrant, Janine L. ; Benjamin, Christopher D. ; Cutler, Anne H. ; Kalled, Susan L. ; Hsu, Yen Ming ; Garber, Ellen A. ; Hess, Donna M. ; Shapiro, Renee I. ; Kenyon, Norma S ; Harlan, David M. ; Kirk, Allan D. ; Burkly, Linda C. ; Taylor, Frederick R. / The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. In: International Immunology. 2004 ; Vol. 16, No. 11. pp. 1583-1594.
@article{9316ff965a744782a7ed0db016158ef3,
title = "The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge",
abstract = "Blockade of the CD154-CD40 co-stimulatory pathway with anti-CD154 mAbs has shown impressive efficacy in models of autoimmunity and allotransplantation. Clinical benefit was also demonstrated in systemic lupus erythematosus (SLE) and idiopathic thrombocytopenia patients with the humanized anti-CD154 mAb, 5C8 (hu5C8). However, thromboembolic complications that occurred during the course of the hu5C8 clinical trials have proven to be a major setback to the field and safe alternative therapeutics targeting the CD154-CD40 pathway are of great interest. Recently, effector mechanisms have been shown to play a part in anti-CD154 mAb-induced transplant acceptance in murine models, while this issue remains unresolved for humoral-mediated models. Herein, aglycosyl anti-CD154 mAbs with reduced binding to FcγR and complement were used as a novel means to test the role of effector mechanisms in non-human primate and murine models not amenable to gene knockout technology. While aglycosyl hu5C8 mAb was relatively ineffective in rhesus renal and islet allotransplantation, it inhibited primary and secondary humoral responses to a protein immunogen in cynomolgus monkeys. Moreover, an aglycosyl, chimeric MR1 mAb (muMR1) prolonged survival and inhibited pathogenic auto-antibody production in a murine model of SLE. Thus, the mechanisms required for efficacy of anti-CD154 mAbs depend on the nature of the immune challenge.",
keywords = "Antibody, Co-stimulation, FcR, Lupus, Transplantation",
author = "Ferrant, {Janine L.} and Benjamin, {Christopher D.} and Cutler, {Anne H.} and Kalled, {Susan L.} and Hsu, {Yen Ming} and Garber, {Ellen A.} and Hess, {Donna M.} and Shapiro, {Renee I.} and Kenyon, {Norma S} and Harlan, {David M.} and Kirk, {Allan D.} and Burkly, {Linda C.} and Taylor, {Frederick R.}",
year = "2004",
month = "11",
day = "1",
doi = "10.1093/intimm/dxh162",
language = "English",
volume = "16",
pages = "1583--1594",
journal = "International Immunology",
issn = "0953-8178",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge

AU - Ferrant, Janine L.

AU - Benjamin, Christopher D.

AU - Cutler, Anne H.

AU - Kalled, Susan L.

AU - Hsu, Yen Ming

AU - Garber, Ellen A.

AU - Hess, Donna M.

AU - Shapiro, Renee I.

AU - Kenyon, Norma S

AU - Harlan, David M.

AU - Kirk, Allan D.

AU - Burkly, Linda C.

AU - Taylor, Frederick R.

PY - 2004/11/1

Y1 - 2004/11/1

N2 - Blockade of the CD154-CD40 co-stimulatory pathway with anti-CD154 mAbs has shown impressive efficacy in models of autoimmunity and allotransplantation. Clinical benefit was also demonstrated in systemic lupus erythematosus (SLE) and idiopathic thrombocytopenia patients with the humanized anti-CD154 mAb, 5C8 (hu5C8). However, thromboembolic complications that occurred during the course of the hu5C8 clinical trials have proven to be a major setback to the field and safe alternative therapeutics targeting the CD154-CD40 pathway are of great interest. Recently, effector mechanisms have been shown to play a part in anti-CD154 mAb-induced transplant acceptance in murine models, while this issue remains unresolved for humoral-mediated models. Herein, aglycosyl anti-CD154 mAbs with reduced binding to FcγR and complement were used as a novel means to test the role of effector mechanisms in non-human primate and murine models not amenable to gene knockout technology. While aglycosyl hu5C8 mAb was relatively ineffective in rhesus renal and islet allotransplantation, it inhibited primary and secondary humoral responses to a protein immunogen in cynomolgus monkeys. Moreover, an aglycosyl, chimeric MR1 mAb (muMR1) prolonged survival and inhibited pathogenic auto-antibody production in a murine model of SLE. Thus, the mechanisms required for efficacy of anti-CD154 mAbs depend on the nature of the immune challenge.

AB - Blockade of the CD154-CD40 co-stimulatory pathway with anti-CD154 mAbs has shown impressive efficacy in models of autoimmunity and allotransplantation. Clinical benefit was also demonstrated in systemic lupus erythematosus (SLE) and idiopathic thrombocytopenia patients with the humanized anti-CD154 mAb, 5C8 (hu5C8). However, thromboembolic complications that occurred during the course of the hu5C8 clinical trials have proven to be a major setback to the field and safe alternative therapeutics targeting the CD154-CD40 pathway are of great interest. Recently, effector mechanisms have been shown to play a part in anti-CD154 mAb-induced transplant acceptance in murine models, while this issue remains unresolved for humoral-mediated models. Herein, aglycosyl anti-CD154 mAbs with reduced binding to FcγR and complement were used as a novel means to test the role of effector mechanisms in non-human primate and murine models not amenable to gene knockout technology. While aglycosyl hu5C8 mAb was relatively ineffective in rhesus renal and islet allotransplantation, it inhibited primary and secondary humoral responses to a protein immunogen in cynomolgus monkeys. Moreover, an aglycosyl, chimeric MR1 mAb (muMR1) prolonged survival and inhibited pathogenic auto-antibody production in a murine model of SLE. Thus, the mechanisms required for efficacy of anti-CD154 mAbs depend on the nature of the immune challenge.

KW - Antibody

KW - Co-stimulation

KW - FcR

KW - Lupus

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=8344276804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8344276804&partnerID=8YFLogxK

U2 - 10.1093/intimm/dxh162

DO - 10.1093/intimm/dxh162

M3 - Article

C2 - 15466914

AN - SCOPUS:8344276804

VL - 16

SP - 1583

EP - 1594

JO - International Immunology

JF - International Immunology

SN - 0953-8178

IS - 11

ER -